Tyme Technologies, Inc. (TYME): Price and Financial Metrics


Tyme Technologies, Inc. (TYME)

Today's Latest Price: $0.95 USD

0.02 (2.57%)

Updated Sep 25 4:00pm

Add TYME to Watchlist
Sign Up

Overall POWR Rating

Sign Up to See Ratings...FREE!

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 233 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

TYME Daily Price Range
TYME 52-Week Price Range

TYME Stock Price Chart Technical Analysis Charts

TYME Price/Volume Stats

Current price $0.95 52-week high $2.04
Prev. close $0.93 52-week low $0.86
Day low $0.91 Volume 412,578
Day high $1.00 Avg. volume 753,075
50-day MA $1.15 Dividend yield N/A
200-day MA $1.28 Market Cap 121.03M

Tyme Technologies, Inc. (TYME) Company Bio

Tyme Technologies, Inc., a clinical-stage pharmaceutical company, focuses on the discovery and development of cancer therapeutics for various oncology indications. It is developing SM-88, a combination therapy in Phase II development for prostate cancer. The company was founded in 2011 and is based in New York, New York.

Most Popular Stories View All

• When Does the Next Bull Run Start?

• Is Now a Good Time to Buy Shares of Carnival Corp.?

• 3 Dividend Stocks with EXPLOSIVE Growth

• Is eBay a Buy at $52?

• 4 DOWNGRADED Stocks to AVOID

View All Top Stories

TYME Latest News Stream

Event/Time News Detail
Loading, please wait...
View All TYME News

TYME Latest Social Stream

Loading social stream, please wait...

View Full TYME Social Stream

Latest TYME News From Around the Web

Below are the latest news stories about Tyme Technologies Inc that investors may wish to consider to help them evaluate TYME as an investment opportunity.

Tyme Technologies: Killing Cancer By Compromising Tumor Cell Metabolism

Tyme Technologies, Inc. (TYME) is an emerging biotechnology company developing Cancer Metabolism-Based Therapies (CMBTs) that are intended to be effective across various solid tumors and hematologic cancers, while having low toxicity profile. The company's therapy is designed to compromise the cancer cell's innate metabolic weaknesses, resulting in cell death through...

Avisol Capital Partners on Seeking Alpha | September 23, 2020

Tyme Technologies to Present at BioNJ’s 10th Annual BioPartnering Conference on October 6, 2020

NEW YORK--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc. (NASDAQ:TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that its leadership team will present at the BioNJ 10th Annual BioPartnering Conference on Tuesday, October 6, 2020. The Company will present its corporate overview for fiscal year 2021 with a special focus on multiple growth opportunities driven by advances in the science of cell metabolism, SM-88 (racemetyrosine) pivotal and late-

Business Wire | September 14, 2020

Tyme Technologies to Present at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22, 2020

Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that its leadership will present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22, 2020. The Company will present its corporate overview for fiscal year 2021 with a special focus on multiple growth opportunities driven by advances in the science of cell metabolism, SM-88 (racemetyrosine) pivotal and late-stage trials in pancreatic cancer, SM-88 HopES trial in ultra-rare metastatic sarcoma, proof-of-concept RESPOnD trial evaluating TYME-19 in COVID-19, and expanding clinical plans for its cancer-metabolism pipeline candidate SM-88 in pancreatic, prostate, breast and hematological cancers.

Yahoo | September 9, 2020

Tyme Technologies offers 2.2M shares for sale

Tyme Technologies ([[TYME]] -2.4%) announces offer and sale of up to 2.17M common shares, issuable upon the exercise of the warrants at an exercise price of $1.80 per share, expiring on April 2, 2024.Upon exercise of warrants, holders will pay ~$3.9M if all of the warrants are exercised in full for cash.Additionally, the...

Seeking Alpha | September 3, 2020

Tyme Technologies to Present at H.C. Wainwright 22nd Annual Global Investment Conference on September 15, 2020

NEW YORK--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that its leadership will participate at the H.C. Wainwright 22nd Annual Global Investment Conference on Tuesday, September 15, 2020. The Company will present its corporate overview for 2020 with a special focus on multiple growth opportunities driven by advances in the science of cell metabolism, SM-88 (racemetyrosine) pivotal and

Business Wire | September 2, 2020

Read More 'TYME' Stories Here

TYME Price Returns

1-mo -12.84%
3-mo -31.16%
6-mo -13.64%
1-year -36.24%
3-year -81.00%
5-year -88.82%
YTD -32.14%
2019 -62.06%
2018 -42.16%
2017 70.13%
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8311 seconds.